Until recently, the treatment of multiple sclerosis (MS) was restricted to symptomatic therapies. Advances in our understanding of the pathogenesis of MS are now resulting in the rapid proliferation of treatment strategies to slow or stop the progression of this disease. Clearly, immunological therapies can improve outcomes in MS and offer hope that this crippling disease can be controlled before patients develop major neurological disabilities. Immunological therapies under investigation for the treatment of MS are taking advantage of dramatic improvements in our understanding of immunoregulation. In addition, immunological treatment of MS is becoming selective relative to myelin antigens, enhancing efficacy and reducing toxicity. The Neuroscientist 2:127-136, 1996
Bever C.The current status of studies of aminopyndines in patients with multiple sclerosis . Ann Neurol1994;36:S118-S121
2.
Bansil S., Cook SD, Rohowsky-Kochan C.Multiple sclerosis: immune mechanism and update on current therapies . Ann Neurol1995;37.S87-S101
3.
Vollmer TL, Waxman SGDemyelinating disorders of the central nervous system. In: Rosenberg RN, editor. Comprehensive neurologyNew York: Raven Press1991;489-523.
4.
Thompson AJ, Kermode AG, Wicks D., et al Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol1991;29:53-62.
5.
Poser CMThe epidemiology of multiple sclerosis: a general overviewAnn Neurol1994;36(Suppl 2):S180-S193
6.
Booss J., Kim JHEvidence for a viral etiology of multiple sclerosis. In. Cook SD, editor. Handbook of multiple sclerosis . New York: Marcel Dekker1990;41-62.
7.
Wynn DR, Rodnguez M., O'Fallon WM, Kurland LTUpdate on epidemiology of multiple sclerosis. Mayo Clin Proc1989;64:808-817.
8.
Ebers GCGenetics and multiple sclerosis: an overview. Ann Neurol1994;36:S12-S14.
9.
Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker1990.
10.
Sibley WA, Bamford CR, Clark K.Clinical viral infections and multiple sclerosis. Lancet1985;1:1313-1315
11.
Abramsky O.Pregnancy and multiple sclerosis. Ann Neurol1994; 36:S38-S41.
12.
Panitch HS, Hirsch RL, Haley AS, Johnson KPExacerbations of multiple sclerosis in patients treated with gamma interferon . Lancet1987;1:893-895.
13.
Beck J., Rondot P., Catinot L., et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokmes trigger off exacerbations? Acta Neurol Scand1988;78:318-323.
14.
Wekerle H., Kimikazu K., Lannes-Vieira J., Lassmann H., Lmmgton C.Animal models. Ann Neurol1994;36:S47-S53.
15.
Cannella B. , Rame CSThe adhesion molecule and cytokme profile of multiple sclerosis. Ann Neurol1995;37:424-435.
16.
Brosnan CF, Selmaj K., Rame CSHypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol1988;18:87-94.
17.
Raine C.The immunology of the multiple sclerosis lesion. Ann Neurol1994;36:S61-S72.
18.
Waxman SGPrerequisites for conduction in demyelinated fibers. Neurology1978;28(Pt 2):27-34.
19.
Sears TA, Bostock H., Sherratt M.The pathophysiology of demyelination and its implications for symptomatic treatment of multiple sclerosis. Neurology1978;28(Pt 2):21-26.
20.
Waxman SGDemyelination in spinal cord injury and multiple sclerosis: what can we do to enhance functional recovery? J Neurotrauma1992;9:S105-S117
21.
Filippi M., Horsfield MA, Momssey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology1994;44:635-641
22.
Hauser SL, Dawson DM, Lehnch JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med1983;308:173-180.
23.
Carter JL, Hafler DA, Dawson DM, Orav J., Wemer HLImmunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology1988;38(Suppl 2):9-14.
Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathiopnne with and without methylprednisolone m multiple sclerosis. Neurology1989;1018-1026.
26.
Goodkm DE, Bailly RC, Teetzen ML, Hertsgaard D., Beatty WWThe efficacy of azathiopnne in relapsing-remitting multiple sclerosis . Neurology1991;41:20-25.
27.
Weinblatt ME , Weissman BN, Hodsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritisArthritis Rheum1992;31:129-137.
28.
Goodkm DE, Rudick RA, VanderBrug Medendorp S., et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol1995;37: 30-40.
29.
Cook SD, Devereux C., Troiano R., et al. Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol1987;22:634-638.
30.
Cook SD, Bansil S., Boos J., et al. Total lymphoid irradiation (TLI) and low-dose predmsone (LDP) in progressive multiple sclerosis (PMS. Neurology1995;45(Suppl 4):A417.
31.
Sipe JC, Romine J., Koziol J., Zyroff J., McMillan R., Beutler E.Cladnbine treatment of chronic progressive (c/p) MS: a double-blind, crossover study with 2+ years' observation. Neurology1995;45 (Suppl 4):A418.
32.
Troiano R.Corticosteroid therapy in acute multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis . New York: Marcel Dekker1990;351-370.
33.
Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in optic neuritis . N Engl J Med1992;326:581-588.
34.
Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith BCThe effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med1993; 329:1764-1769.
35.
Milligan NM , Newcombe R., Compston Das.A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects . J Neurol Neurosurg Psychiatry1987;50:511-516.
36.
Rudge P.Cyclosporine and multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker1990;439-454.
37.
Weinstock-Guttman B., Ransohoff RM, Kinkel P., Rudick R.The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol1995;37:7-15.
38.
IFNB Study Group.Interferon β-1b is effective in relapsmg-remitting multiple sclerosis. Neurology1993;43:655-661.
39.
Paty DW, Li Dkb, UBC MS/MRI Study Group, IFNB MS Study Group.Interferon β-1b is effective in relapsing-remitting multiple sclerosisNeurology1993;43:662-667.
40.
Ifnb MSStudy Group, UBC MS/MRI Analysis Group.Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology1995;45:1277-1285.
41.
Jacobs LLA phase III trial of intramuscular recombinant interferon beta as treatment for exacerbation-remitting multiple sclerosis : design and conduct of study and baseline characteristics of patients. In press.
42.
Durelli L., Bongioanni MR, Cavallo R., et al. Chronic systemic high-dose recombinant interferon α-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology1994;44:406-413.
43.
Calabresi PA , Hanham A., Carlino J., Olsen H., et al. Report of an ongoing phase I trial of recombinant transforming growth factor-β 2 (TGF-β2) in chronic progressive multiple sclerosis. Neurology1995;45 (Suppl 4):A417.
44.
Brosnan CF, Cannella B., Battistini L., Raine CSCytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology1995;45:S16-S21.
45.
Karussis D. , Meiner A., Lehmann D., et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide : results of a double-blind placebo-controlled study with monthly MRI evaluation . Neurology1995;45 (Suppl 4):A417.
46.
Hodgkinson SJ , Steinman L.Monoclonal antibodies for treatment of multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. New York : Marcel Dekker1990;481-492.
47.
Lmdsey JW, Hodgkinson S., Mehta R., Mitchel D., Enzmann D., Steinman L.Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis . Ann Neurology1994;36:183-189.
48.
Webb C., Teitelbaum D., Arnon R., Sela M.In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol1973;3:279-286.
49.
Fndkis-Hareli M., Teitelbaum, D., Gurevitch E., et al. Direct bindmg of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity . Proc Natl Acad Sci U S A1994;91:4872-4876.
50.
Johnson KP, Brooks BR, Cohen J., et al. Copolymer 1 (Cop 1) reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology1995;45:1268-1276.
51.
Nelson P., Weiner HLOral tolerance in the treatment of autoimmune disease. Practical Allergy & Immunology1994;9:164-174.
52.
Weiner HL, Mackm GA, Matsui M., et al. Double-blind pilot trial of oral tolenzation with myelin antigens in multiple sclerosis. Science1993;259:1321-1324.
